hims & hers fda warning letter compounded semaglutide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Takes Aim at Hims

Alternative medications: Discuss alternative medications with your health care provider

AI-powered form filling tools like Instafill.ai can help by automatically formatting dates correctly and flagging mismatches before submission

These specific taxa are the primary producers of butyrate, the most critical SCFA for maintaining intestinal health

Another study showed that acute administration of exenatide was associated with increased hepatic glucose uptake during an oral glucose tolerance test (OGTT) and a reduction in endogenous glucose production, reinforcing the hypothesis of a direct action of GLP-1 on the liver [12]

Increasing feelings of fullness : It will result in diminished calories consumed and subsequent weight loss